Summary
Between January 1969 and December 1988, 482 patients were treated for Hodgkin's disease at the Leiden University Hospital. All cases were routinely recorded in the Hospital Information System, which has an active annual follow-up. Of all patients, 57% remained relapse free. According to the kinds of treatment they received, the following major categories were established: radiotherapy only (28.2%), chemotherapy only (20.1%), only initial combination of radiotherapy and chemotherapy (34.2%), all other combinations of radio- and chemotherapy (15.4%), or not registered (2.1%). Twenty-seven second cancers were observed; six leukemias, five non-Hodgkin lymphomas, and 16 solid tumors. Of all solid tumors only nine occurred in relapse-free patients. The overall relative risk of second cancers increased with the duration of follow-up. Using general population incidence rates to calculate expected numbers, the risk for developing leukemia, non-Hodgkin lymphoma, and solid tumors was increased 36-fold, 31-fold, and 2.4-fold, respectively. The cumulative risk of developing a second cancer 10 years after diagnosis of Hodgkin's disease was 7% for both the radiotherapy-only and the initial combination of radio- and chemotherapy group. It was 16% and 17% for the chemotherapy-only and the other combinations of radio- and chemotherapy group, respectively. Multivariate analysis (using the Cox regression model) show an increased risk of second cancers (RR=0.7) when a relapse of Hodgkin's disease resulting in increasing cumulative therapy occurred. Age at diagnosis of Hodgkin's disease was an important determinant for the risk of non-Hodgkin lymphoma and solid tumors. Cumulative chemotherapy intensity was an important factor in increasing leukemic risk in a dose-response fashion. Apart from this, the stage of Hodgkin's disease, although closely related to the kind of therapy, seemed to have an independent effect on leukemic risk.
Similar content being viewed by others
References
Baccarani M, Bosi A, Papa G (1980) Second malignancy in patients treated for Hodgkin's disease. Cancer 46: 1735–1740
Blayney DW, Longo DL, Young RC, Greene MH, Hubbard SM, Postal MG, Duffey PL, DeVita VT (1987) Decreasing risk of leukemia with prolonged follow-up after chemotherapy and radiotherapy for Hodgkin's disease. N Engl J Med 316: 710–714
Central Bureau for Statistics (1983) Morbidity and Mortality. “Centraal Bureau voor de Statistiek (1983) Morbiditeit en Mortaliteit”. Maandbericht Gezondheid (CBS) 11: 14–15
Cimino G, Papa G, Tura S, et al. (1991) Second primary cancer following Hodgkin's disease: updated results of an Italian multicentric study. J Clin Oncol 9: 432–437
Cox DR (1972) Regression models and life tables. J R Stat Soc B 34: 187–220
Henry-Amar M, Pellae-Cosset B, Bayle-Weisgerber C, Hayat M, Cosset JM, Carde P, Tubiana M (1989) Risk of secondary acute leukemia and pre-leukemia after Hodgkin's disease. In: Diehl V, Pfreundschuh M, Loffler M (eds) New aspects in the diagnosis and treatment of Hodkin's disease. Recent Results Cancer Res 117: 270–283
Kaldor AM, Day NE, Band P, Choi NW, Clarke EA, Coleman MP, Hakama M, Koch M, Langmark F, Neal FE, Pettersson F, Pompe-Kirn V, Prior P, Storm HH (1987) Second malignancies following testicular cancer, ovarian cancer and Hodgkin's disease: an international collaborative study among cancer registries. Int J Cancer 39: 571–582
Kaldor JM, Day NE, Clarke AC, et al. (1990) Leukemia following Hodgkin's disease. N Engl J Med 322: 7–13
Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481
Leeuwen FE van, Somers R, Taal BG, Van Heerde P, Coster B, Dozeman T, Huisman SJ, Hart AAM (1989) Increased risk of lung cancer, non-Hodgkin lymphoma and leukemia following Hodgkin's disease. J Clin Oncol 7: 1046–1058
List AF, Greer JP, Cousar JB, et al. (1986) Non-Hodgkin's lymphoma after treatment of Hodgkin's disease: association with Epstein-Barr vims. Ann Intern Med 105: 668–673
Loeschler LJ, Welch-McCaffrey D, Leigh SA, Huffman B, Meyskens FL (1989) Surviving adult cancers. Part 1: Physiologic Effects. Ann Intern Med 111: 411–432
Mantel N (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50: 163–170
Monson RR (1990) Occupational epidemiology, 2nd Edition. CRC Press, Boca Raton, FL: 105–114
Papa G, Mauro FR, Anselmo AP, et al. (1984) Acute leukemia in patients treated for Hodgkin's disease. Br J Haematol 58: 43–52
Pedersen-Bjergaard J, Larsen SO, Struck J, Hansen HH, Specht L, Ersboll J, Hansen MM, Nissen N (1987) Risk of therapy-related leukaemia and preleukaemia after Hodgkin's disease. Lancet 1: 83–88
Selby P, McElwain TJ (1987) Hodgkin's disease. Blackwell Scientific, Oxford
Tucker MA, Coleman CN, Cox RS, Varghese A, Rosenberg SA (1988) Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med 318: 76–81
Vandenbroucke JP (1982) A shortcut method for calculating the 95 percent confidence interval of the standardized mortality ratio. Am J Epidemiol 115: 303–304
Vandenbroucke JP, Hofman A (1988) The Essentials of Epidemiology. “Grondslagen der epidemiologie”. Wetenschappelijke Uitgeverij Bunge, Utrecht
Zwetsloot-Schonk JHM, Snitker P, Vandenbroucke JP, Bakker AR (1989) Using Hospital Information Systems for clinical epidemiologic research. Med Inform 14: 53–62
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sont, J.K., van Stiphout, W.A.H.J., Noordijk, E.M. et al. Increased risk of second cancers in managing Hodgkin's disease: the 20-year Leiden experience. Ann Hematol 65, 213–218 (1992). https://doi.org/10.1007/BF01703947
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01703947